| Heading: |
Animal Experiments |
| Question ID: |
1812072 |
| UIN: |
59437 |
| House: |
Commons |
| Date tabled: |
2025-06-12 |
| Asking Member ID: |
5089 |
| Asking Member display name: |
Ben Obese-Jecty
|
| Asking Member handle: |
BenObeseJecty
|
| Asking Member Twitter reference: |
@BenObeseJecty
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Science, Innovation and Technology, whether he plans to replace animal testing in the development of (a) monoclonal antibody therapies and (b) other drugs with more effective human-specific methods. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-20 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4822 |
| Answering Member display name: |
Feryal Clark
|
| Answering Member handle: |
FeryalClark
|
| Answering Member Twitter reference: |
@FeryalClark
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
Regulatory approval processes already permit human-specific methods for drug testing where humans are the only relevant pharmacological species and the drug’s mechanism of action is well-defined and clinical monitoring is in place. This can include monocl... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
216 |
| Answering body name: |
Department for Science, Innovation and Technology |
| Tweeted: |
true |